112 related articles for article (PubMed ID: 29517197)
1. Review of hereditary leiomyomatosis renal cell carcinoma with focus on clinical and pathobiological aspects of renal tumors.
Kuroda N; Ohe C; Kato I; Furuya M; Baba M; Nagashima Y; Nakatani Y; Murakami I; Zhou M; Michal M; He O; Amin MB
Pol J Pathol; 2017; 68(4):284-290. PubMed ID: 29517197
[TBL] [Abstract][Full Text] [Related]
2. In deep bioinformatic characterization of a novel fumarate hydratase variant FH c.199T > G; (p.Tyr67Asp) in hereditary leiomyomatosis and renal cell carcinoma.
Chami A; de Souza Zózimo TR; Alves TM; Matosinho CGR; Santos C; Simões MM; Cabral WLR; de Paula Ricardo BF; da Silva Filho AL; Carvalho MRS; da Conceição Braga L
Fam Cancer; 2023 Oct; 22(4):481-486. PubMed ID: 37316640
[TBL] [Abstract][Full Text] [Related]
3. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Smith SC; Trpkov K; Chen YB; Mehra R; Sirohi D; Ohe C; Cani AK; Hovelson DH; Omata K; McHugh JB; Jochum W; Colecchia M; Amin M; Divatia MK; Hes O; Menon S; Werneck da Cunha I; Tripodi S; Brimo F; Gill AJ; Osunkoya AO; Magi-Galluzzi C; Sibony M; Williamson SR; Nesi G; Picken MM; Maclean F; Agaimy A; Cheng L; Epstein JI; Reuter VE; Tickoo SK; Tomlins SA; Amin MB
Am J Surg Pathol; 2016 Nov; 40(11):1457-1472. PubMed ID: 27635946
[TBL] [Abstract][Full Text] [Related]
4. Cryptic splice mutation in the fumarate hydratase gene in patients with clinical manifestations of Hereditary Leiomyomatosis and Renal Cell Cancer.
Crooks DR; Cawthon GM; Fitzsimmons CM; Perez M; Ricketts CJ; Vocke CD; Yang Y; Middelton L; Nielsen D; Schmidt LS; Tandon M; Merino MJ; Ball MW; Meier JL; Batista PJ; Linehan WM
Hum Mol Genet; 2023 Nov; 32(22):3135-3145. PubMed ID: 37561409
[TBL] [Abstract][Full Text] [Related]
5. Segregation, immunohistochemical, molecular and functional analyses classify a novel missense variant in fumarate hydratase (FH) as pathogenic.
Ouchene L; Wilde B; Chan-Pak-Choon F; Camacho Valenzuela J; Brimo F; Witkowski L; Christofk H; Domecq C; Fu L; Weber E; Lemieux Anglin B; Netchiporouk E; Foulkes WD
Genes Chromosomes Cancer; 2024 Feb; 63(2):e23221. PubMed ID: 38682608
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients.
Choi Y; Keam B; Kim M; Yoon S; Kim D; Choi JG; Seo JY; Park I; Lee JL
Cancer Res Treat; 2019 Oct; 51(4):1549-1556. PubMed ID: 30913859
[TBL] [Abstract][Full Text] [Related]
7. The use of Clinicopathological, immunohistochemistry and molecular detection in the diagnosis of fumarate hydratase-deficient uterine leiomyomas.
Zhang X; Wang C; Shen D
Pathol Res Pract; 2024 Jan; 253():154916. PubMed ID: 38029712
[TBL] [Abstract][Full Text] [Related]
8. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment.
Menko FH; Maher ER; Schmidt LS; Middelton LA; Aittomäki K; Tomlinson I; Richard S; Linehan WM
Fam Cancer; 2014 Dec; 13(4):637-44. PubMed ID: 25012257
[TBL] [Abstract][Full Text] [Related]
9. Dermatologists might be the first to suspect hereditary leiomyomatosis and renal cell carcinoma syndrome.
González-Guerra E; Conde Taboada A; Cortés Toro JA; López Bran E; Pérez Segura P
An Bras Dermatol; 2023; 98(5):696-698. PubMed ID: 37230921
[No Abstract] [Full Text] [Related]
10. Comparison of 2SC, AKR1B10, and FH Antibodies as Potential Biomarkers for FH-deficient Uterine Leiomyomas.
Ahvenainen T; Kaukomaa J; Kämpjärvi K; Uimari O; Ahtikoski A; Mäkinen N; Heikinheimo O; Aaltonen LA; Karhu A; Bützow R; Vahteristo P
Am J Surg Pathol; 2022 Apr; 46(4):537-546. PubMed ID: 34678832
[TBL] [Abstract][Full Text] [Related]
11. Genetic and clinical characterization of a novel FH founder mutation in families with hereditary leiomyomatosis and renal cell cancer syndrome.
Sánchez-Heras AB; Dámaso E; Castillejo A; Robledo M; Teulé A; Lázaro C; Sánchez-Martínez R; Zúñiga Á; López-Fernández A; Balmaña J; Robles L; Ramon Y Cajal T; Castillejo MI; Ibañez RP; Sevila CM; Sánchez-Mira A; Escandell I; Gómez L; Berbel P; Soto JL
Orphanet J Rare Dis; 2024 Jan; 19(1):26. PubMed ID: 38279137
[TBL] [Abstract][Full Text] [Related]
12. The Role of Morphology in Predicting Fumarate Hydratase-deficient Uterine Leiomyomas in Young Women.
Bayram A; Bagbudar S; Sozen H; Onder S; Yavuz E
Appl Immunohistochem Mol Morphol; 2023 Nov-Dec 01; 31(10):657-660. PubMed ID: 37751278
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic approach to eosinophilic renal neoplasms.
Kryvenko ON; Jorda M; Argani P; Epstein JI
Arch Pathol Lab Med; 2014 Nov; 138(11):1531-41. PubMed ID: 25357116
[TBL] [Abstract][Full Text] [Related]
14. Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism.
Valcarcel-Jimenez L; Frezza C
Br J Cancer; 2023 Nov; 129(10):1546-1557. PubMed ID: 37689804
[TBL] [Abstract][Full Text] [Related]
15. Multiple cutaneous and uterine leiomyomatosis: Reed's syndrome.
Bhanja DB; Sil A; Sikder B; Chandra A
BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38417936
[TBL] [Abstract][Full Text] [Related]
16. Fumarate hydratase inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis induction.
Kerins MJ; Milligan J; Wohlschlegel JA; Ooi A
Cancer Sci; 2018 Sep; 109(9):2757-2766. PubMed ID: 29917289
[TBL] [Abstract][Full Text] [Related]
17. Hereditary leiomyomatosis and renal cell cancer linked with FH mutations.
Millington GWM
Clin Exp Dermatol; 2023 Oct; 48(11):1301-1303. PubMed ID: 37421326
[No Abstract] [Full Text] [Related]
18. Increased risk of cancer in patients with fumarate hydratase germline mutation.
Lehtonen HJ; Kiuru M; Ylisaukko-Oja SK; Salovaara R; Herva R; Koivisto PA; Vierimaa O; Aittomäki K; Pukkala E; Launonen V; Aaltonen LA
J Med Genet; 2006 Jun; 43(6):523-6. PubMed ID: 16155190
[TBL] [Abstract][Full Text] [Related]
19. [FH (Fumarate Hydratase)-deficient renal cell carcinoma: A case report].
Allaume P; Kammerer-Jacquet SF; Papadopoulos S; Rioux-Leclercq N
Ann Pathol; 2023 Sep; 43(5):417-420. PubMed ID: 36822902
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma.
Bai J; Li X; Wen Y; Lu Q; Chen R; Liu R; Shangguan T; Ye Y; Lin J; Cai W; Kang D; Chen J
Aging (Albany NY); 2024 Feb; 16(4):3631-3646. PubMed ID: 38376408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]